This site contains affiliate links. We may earn a commission at no extra cost to you. Our methodology

CompareGLP-1

HomeVerdictsPrice Watch

Price Watch

GLP-1 Price Tracker: What Changed This Month (May 2026)

Prices verified May 2026 · Compare GLP-1 Editorial Team

Updated: May 2026. We track GLP-1 medication pricing across brand-name and compounded markets monthly. Bookmark this page for the latest.

May 2026 Market Summary

The GLP-1 pricing landscape continues to evolve. Brand-name pricing has seen downward pressure from manufacturer savings programs and increasing insurance coverage. Compounded pricing remains competitive but faces uncertainty from ongoing FDA enforcement. Here's what moved this month.

Brand-Name Pricing

Feature Price Trend
Wegovy (retail) ~$1,349/mo Stable
Zepbound (retail) ~$1,080/mo Stable
Ozempic (retail) ~$935/mo Stable
Mounjaro (retail) ~$1,050/mo Stable
Rybelsus 14mg (retail) ~$935/mo Stable

Brand-name retail pricing has been relatively stable. The real action is in savings programs and insurance coverage expansion. Novo Nordisk's NovoCare and Eli Lilly's LillyDirect continue to expand eligibility for manufacturer savings, and more commercial insurance plans are adding GLP-1 weight management coverage.

Compounded Pricing

Feature Range Trend
Compounded semaglutide (low) $130–149/mo Stable to slightly down
Compounded semaglutide (mid) $199–299/mo Stable
Compounded tirzepatide $199–400/mo Limited availability

Compounded semaglutide pricing has remained competitive as the number of telehealth providers continues to grow. Compounded tirzepatide availability is more constrained due to FDA enforcement actions, which has kept prices higher where it's available.

Key Developments to Watch

Orforglipron approval timeline: Eli Lilly's oral GLP-1 agonist could receive FDA approval in 2026–2027. If approved, it could significantly disrupt both brand-name and compounded pricing by offering a convenient, potentially lower-cost oral option.

Medicare coverage: Legislation to extend GLP-1 coverage under Medicare continues to advance. If enacted, this would dramatically expand the addressable market and could put downward pressure on brand-name pricing.

Compounding enforcement: The FDA continues to evaluate compounding regulations. Any significant enforcement changes could rapidly affect compounded medication availability and pricing.

Prices change. This page is updated monthly but may not reflect promotional pricing or short-term offers. Always verify current pricing directly with the provider before committing.

Check Current Pricing

Embody

Injectable semaglutide at transparent, stable pricing.

$149 first month / $299 refills

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

Yucca Health

Among the lowest verified monthly prices for compounded semaglutide.

$146/mo semaglutide (6-month plan)

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

Oak Longevity

Competitive semaglutide pricing.

From $130/mo semaglutide

Check Eligibility → Paid link

Compounded medications are not FDA-approved.

Related Verdicts